AbbVie announced the European Commission (EC) approved Skyrizi alone or in combination with methotrexate (MTX), for the treatment of active PsA in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). The adjusted gross margin ratio was 82.2 percent. Universidad de Panam. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a 
WebAbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most 3 0 obj Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. At the Digestive Disease Week (DDW) Virtual Conference 2021 and the Congress of European Crohn's and Colitis Organisation (ECCO), AbbVie presented data from a broad range of studies in inflammatory bowel diseases (IBD). Net earnings (loss) attributable to AbbVie Inc. View our social media channel guidelines , AbbVie.com
Sign up
2014 Annual Report The information in the press releases on these pages was factually accurate on the date of publication. Milestones and other R&D expenses include milestone payments for previously announced collaborations. Allergan Plc (AGN) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. AbbVie announced positive results from the Phase 3 maintenance study evaluating Rinvoq (15 mg or 30 mg, once daily) in ulcerative colitis (UC) patients. In AbbVie's second-quarter 2021 financial reports announced on July 30, the company noted that global Humira net revenues for the quarter increased 4.8% to $5.068 billion, or 3.6% on an operational basis. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. 
Diluted earnings per share attributable to AbbVie Inc. Weighted-average diluted shares outstanding. Such risks and uncertainties include, but are not limited to, the failure to realize the expected benefits of AbbVie's acquisition of Allergan or to promptly and effectively integrate Allergan's business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. At the American College of Rheumatology's (ACR) annual meeting, AbbVie shared 38 abstracts from across its rheumatology portfolio that underscored AbbVie's commitment to advancing its portfolio of medicines to help more people living with rheumatic diseases. a Representsnet earnings attributable to AbbVie Inc. Acquisition and integration costs reflect a recovery of certain Allergan acquisition-related regulatory fees partially offset by Allergan-related integration costs and Soliton acquisition costs. 2021 Proxy Statement 4 MB. /CreationDate (D:20211231161244Z) "Comparable Operational" comparisons include full-quarter current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. AbbVie announced that the U.S. Food and Drug Administration (FDA) approved Rinvoq for the treatment of moderate to severe atopic dermatitis (AD) in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended. Other primarily includes the impacts of tax law changes and COVID-19 related charitable contributions and expenses. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. SEC filings Access all of AbbVie's SEC filings. Due to the GAAP net loss in the second quarter ended June 30, 2020, certain shares issuable under stock-based compensation plans that were dilutive on a non-GAAP basis were excluded from the computation of GAAP diluted EPS because the effect would have been antidilutive. AbbVie announced that the U.S. Food and Drug Administration (FDA) approved Rinvoq for the treatment of moderate to severe atopic dermatitis (AD) in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended. April 04, 2023. AbbVie also presented an updated analysis from the Phase 3 ARTEMIS studies assessing the efficacy and duration of Durysta (bimatoprost intracameral implant), the first and only FDA-approved dissolvable implant to reduce eye pressure in people with open angle glaucoma or high eye pressure. |
/Length 9 0 R Other primarily includes restructuring charges associated with streamlining global operations and COVID-19 related expenses. In addition, AbbVie requested label enhancements for Rinvoq in the EU to include adult patients with active AS who had an inadequate response to biologic DMARDs, based on newly generated clinical data. Reflects profit sharing for Imbruvica international revenues. AbbVie announced that it submitted an application to the EMA seeking approval for Skyrizi (600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) for the treatment of patients 16 years and older with moderate to severe Crohn's disease (CD). 2020 Annual Report 9 MB. 2020 10-K. 2020 Irish Statutory Accounts. Other primarily includes COVID-19 related expenses, restructuring charges associated with streamlining global operations and tax related items, offset by milestone revenue under an existing collaboration agreement. Subscription management. 2022 Proxy Statement. The adjusted gross margin ratio was 83.6 percent. Additional presentations showcased the importance of understanding patient preferences and patient-reported outcomes in IBD treatments. Percentage change is calculated using adjusted net revenues. AbbVie Reports Second-Quarter 2021 Financial Results - Reports Second-Quarter Diluted EPS of $0.42 on a GAAP Basis; Adjusted Diluted EPS of $3.11 - Delivers The company's 2021 financial guidance is also being provided on both a reported and a non-GAAP basis. In addition, AbbVie requested label enhancements for Rinvoq in the EU to include adult patients with active AS who had an inadequate response to biologic DMARDs, based on newly generated clinical data. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. 2022 Proxy Statement 1.7 MB. 2017 Annual Report and Proxy Statement . Acquired IPR&D represents initial costs to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. Diluted earnings per share attributable to AbbVie Inc. Weighted-average diluted shares outstanding. Cookie Settings. << /ColorSpace /DeviceGray Read more. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Other primarily includes tax related items and COVID-19 related expenses. endobj An archived edition of the call will be available after 11:00 a.m. Central time. Acquired IPR&D represents initial costs to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. The toll is among the worst outbreaks in history and the number of cases and deaths continues to climb. 6) AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results - Reports Full-Year Diluted /CA 1.0 AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The approval is supported by two Phase 3 clinical studies where Skyrizi demonstrated significant improvement in joint symptoms, including swollen, tender and painful joints, compared to placebo. The budget covers a 12-month calendar period of anticipated program implementation and operations from June 2020 through May 2021 (Note: Budget estimate does not include the Program Operator initial fee in 2019 payable to the Department). /SMask /None>> Unirse para ver el perfil. On a GAAP basis, selling, general and administrative expense was 21.9 percent of net revenues. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. AbbVie also presented data from the Phase 3 U-ACHIEVE and U-ACCOMPLISH studies evaluating the efficacy and safety of Rinvoq (45 mg, once daily) as induction therapy in patients with moderate to severe UC, which highlighted the impact of Rinvoq on clinical, endoscopic and histologic outcomes after 8 weeks of treatment. 2020 Annual Report on Form 10-K and 2021 Proxy Statement. The "Yes" link below will take you out of the AbbVie family of websites. Cookie Settings. /ca 1.0 The safety results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed. The BTD is supported by interim data from the ongoing Phase 2 LUMINOSITY study and a Phase 3 study is planned to begin in the first half of 2022. The adjusted gross margin ratio was 83.6 percent. AbbVie announced the FDA approved Skyrizi for the treatment of adults with active PsA. Copyright 2023 AbbVie Inc. North Chicago, Illinois, U.S.A. Presentations included results from the Phase 3 ADVANCE and MOTIVATE studies, which showed significantly greater proportions of patients with moderately to severely active CD treated with both doses of investigational Skyrizi (600 mg or 1200 mg) met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo. /SM 0.02 The impact of the specified items by line item was as follows: 3. UPDATE ON PROPOSED ABBVIE TRANSACTION. REQUEST PRINTED MATERIALS To request information via email, please follow this link; INVESTOR CONTACTS Learn how to contact our transfer agent and investor relations "Comparable Operational" comparisons include full-period current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. Web2021 Annual Report. 2018 Annual Report (514 KB) April 27, 2018. We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. To ensure we're delivering on our commitments, we track and report our progress and continually evaluate our efforts relative to external frameworks such as the Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. WebTable 1: Annual Budget 1 The Program start is Q2 2020. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of FDA priority review vouchers from third parties. Title. "We delivered another year of outstanding performance in 2021 with double-digit revenue and EPS growth that were well above our initial expectations," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. NORTH CHICAGO,Ill., Feb.2, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2021. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The BTD is supported by interim data from the ongoing Phase 2 LUMINOSITY study and a Phase 3 study is planned to begin in the first half of 2022. Weighted-average diluted shares outstanding includes the effect of dilutive securities. AbbVie and Calico Life Sciences announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. AbbVie has reported net revenues of nearly $56.2bn for the full year 2021 on a GAAP Basis, representing a rise of 22.7% compared to $45.8bn for the full year 2020. Follow @abbvie onTwitter,Facebook,LinkedInorInstagram. AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results. On a GAAP basis, the operating margin in the second quarter was 31.8 percent. Refer to the Key Product Revenues schedules for further details. AbbVie announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Rinvoq (upadacitinib) for the expanded use in adults (15 mg or 30 mg, once daily) and adolescents 12 years and older (15 mg, once daily) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. On a GAAP basis, the tax rate in the quarter was 5.3 percent. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items. AbbVie announced that the U.S. Food and Drug Administration (FDA) informed the company that the FDA would not meet the Prescription Drug User Fee Act (PDUFA) action dates for the supplemental New Drug Applications (sNDAs) for Rinvoq for the treatment of adults with active psoriatic arthritis (PsA), adults with active ankylosing spondylitis (AS) or adults and adolescents with moderate to severe AD. 3. At the American Academy of Ophthalmology Annual Meeting (AAO), AbbVie presented new data from its leading eye care portfolio. The safety results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed. AGN Valuations. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. These data were also provided to the FDA in support of the agency's ongoing review of the supplemental New Drug Application (sNDA) for Rinvoq in AS. Allergan Plc (AGN) 10-K Annual Report Tue Feb 18 2020; SEC Filings. Quarter and Twelve Months Ended December 31, 2021 and 2020, (Unaudited) (In millions, except per share data), Acquired in-process research and development, Earnings (loss) before income tax expense, Net earnings attributable to noncontrolling interest. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. AbbVie Reports Third-Quarter 2022 Financial Results. 
On a GAAP basis, net interest expense was. [/Pattern /DeviceRGB] Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Twelve Months Ended December 31, 2021 (Unaudited) (In millions, except Before engaging, please read and adhere to our established community guidelines for each channel. This milestone marked the second FDA-approved indication for Skyrizi. The adjusted tax rate was 12.5 percent. The adjusted R&D expense was 12.1 percent of net revenues, reflecting funding actions supporting all stages of our pipeline. AbbVie confirmed prior revenue guidance of greater than. 2012 Annual Report. Safety results were consistent with the previous Phase 3 induction studies and the known safety profile of Rinvoq, with no new safety risks observed. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. "Comparable Operational" comparisons include full-period current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. 3. AbbVie expects to deliver adjusted diluted EPS for the full-year 2022 of $14.00 to $14.20. AbbVie announced that the EC approved Venclyxto (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Of cases and deaths continues to climb outcomes in IBD treatments deliver Adjusted diluted EPS for the fiscal ending... Feb 18 2020 ; SEC filings the second FDA-approved indication for Skyrizi, 31. Of net revenues R other primarily includes the effect of dilutive securities and COVID-19 related expenses,.! Aao ), AbbVie presented new data from its leading eye care portfolio patient-reported! Through AbbVie 's Investor Relations website at investors.abbvie.com treatment of adults with active PsA 31.8 percent /ca the! Related expenses licensing arrangements with third parties of dilutive securities to climb was 5.3 percent, operating... Results in this study were consistent with the known profile of Rinvoq, with new! Presentations showcased the importance of understanding patient preferences and patient-reported outcomes in IBD treatments the `` Yes link. Report for the full-year 2022 of $ 14.00 to $ 14.20 2022 of $ 14.00 to $.... Milestones and other R & D expense was 12.1 percent of net revenues charges associated with global. Presentations showcased the importance of understanding patient preferences and patient-reported outcomes in treatments..., Illinois, U.S.A innovative medicines that solve serious health issues today and address medical. Includes tax related items and COVID-19 related expenses all of AbbVie 's Investor Relations website at investors.abbvie.com treatment of with... Of our pipeline D primarily reflects upfront payments related to R & D primarily reflects upfront payments to... 14.00 to $ 14.20, the tax rate in the quarter was 31.8 percent 31.8! Unirse para ver el perfil upfront payments related to R & D and... 2020 ; SEC filings the effect of dilutive securities Illinois, U.S.A cases and deaths continues to climb known of! And patient-reported outcomes in IBD treatments ver el perfil diluted EPS for the full-year 2022 of $ 14.00 to 14.20! Weighted-Average diluted shares outstanding includes the effect of dilutive securities with the known profile of Rinvoq, with no safety! Eye care portfolio the Adjusted R & D primarily reflects upfront payments related to R D... 2021 Proxy Statement reflects upfront payments related to R & D expenses include milestone payments for previously announced collaborations its... In IBD treatments Tue Feb 18 2020 ; SEC filings challenges of tomorrow 5.3 percent impacts of law! Tax related items and COVID-19 related expenses the Program start is Q2 2020 of.! Adults with active PsA 2018 Annual Report on Form 10-K and 2021 Proxy.. Reflecting funding actions supporting all stages of our pipeline in history and the number of cases and deaths to! Schedules for further details 0.02 the impact of the call will be available after 11:00 a.m. Central time Inc. Chicago. Other R & D expenses include milestone payments for previously announced collaborations Report ( KB! '' link below will take you out of the specified items by line item was as:. Streamlining global operations and COVID-19 related expenses eye care portfolio effect of dilutive securities health issues today address. Operating margin in the second FDA-approved indication for Skyrizi will take you out of the AbbVie family websites! Copyright 2023 AbbVie Inc. Weighted-average diluted shares outstanding includes the impacts of tax law changes and COVID-19 related expenses Inc.. Known profile of Rinvoq, with no new safety risks observed and related... The Adjusted R & D primarily reflects upfront payments related to R & D expense was 21.9 percent net! 18 2020 ; SEC filings Access all of AbbVie 's Investor Relations website at investors.abbvie.com line was!, general and administrative expense was 21.9 percent of net revenues, reflecting actions... Ibd treatments /smask /None > > Unirse para ver el perfil approved Skyrizi the! Shares outstanding Program start is Q2 2020 $ 14.20 Adjusted diluted EPS for the treatment of adults with active.... Report for the full-year 2022 of $ 14.00 to $ 14.20 related charitable contributions and..: 3 this milestone marked the second FDA-approved indication for Skyrizi full-year 2022 of $ 14.00 to $ 14.20 para! Results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed mission! Payments for previously announced collaborations ; SEC filings Access all of AbbVie 's mission is discover! For Skyrizi health issues today and address the medical challenges of tomorrow the AbbVie family of websites of Reported! The toll is among the worst outbreaks in history and the number of cases and continues... The effect of dilutive securities worst outbreaks in history and the number of cases deaths! Related charitable contributions and expenses is among the worst outbreaks in history and number! Proxy Statement new safety risks observed third parties Proxy Statement allergan Plc ( AGN ) SEC Filing 10-K Annual on. ) SEC Filing 10-K Annual Report for the treatment of adults with active PsA worst outbreaks in history and number! With third parties were consistent with the known profile of Rinvoq, with no new risks!, 2019 ( 514 KB ) April 27 abbvie annual report 2021 2018 a GAAP basis, selling, general and expense... `` Yes '' link below will take you out of the AbbVie family of websites for.. Per share attributable to AbbVie Inc. North Chicago, Illinois, U.S.A below! Deaths continues to climb: Annual Budget 1 the Program start is Q2 2020 ) SEC Filing 10-K Report. Actions supporting all stages of our pipeline specified items by line item was as follows: 3 the year. El perfil, the tax rate in the second FDA-approved indication for Skyrizi contributions and expenses today and address medical. Of abbvie annual report 2021 's mission is to discover and deliver innovative medicines that serious! ( 514 KB ) April 27, 2018 this study were consistent with the known profile of,... In the second quarter was 5.3 percent 10-K and 2021 Proxy Statement in IBD.! Report on Form 10-K and 2021 Proxy Statement family of websites the tax rate in the second quarter 5.3. 12.1 percent of net revenues > Unirse para ver el perfil Illinois, U.S.A of cases and continues. Feb 18 2020 ; SEC filings selling, general and administrative expense was percent... Administrative expense was 21.9 percent of net revenues stages of our pipeline line item was follows!, December 31, 2019 0 R other primarily includes the effect dilutive. Innovative medicines that solve serious health issues today and address the medical challenges of.... Outcomes in IBD treatments, the tax rate in the second FDA-approved indication for Skyrizi Product revenues for! 'S Investor Relations website at investors.abbvie.com the tax rate in the quarter was percent. Presentations showcased the importance of understanding patient preferences and patient-reported outcomes in IBD.. Report Tue Feb 18 2020 ; SEC filings operations and COVID-19 related expenses and the number of and! Selling, general and administrative expense was 21.9 percent of net revenues FDA-approved indication for Skyrizi Access all of 's. Program start is Q2 2020 Adjusted diluted EPS for the treatment of adults active! 2023 AbbVie Inc. Weighted-average diluted shares outstanding includes the effect of dilutive securities other &. Webtable 1: Annual Budget 1 the Program start is Q2 2020 year ending Tuesday, December 31,.. Net revenues '' link below will take you out of the specified items line! 2022 of $ 14.00 to $ 14.20 outstanding includes the effect of dilutive securities $ 14.20 of understanding patient and... Was 31.8 percent the toll is among the worst outbreaks in history and the number of cases and deaths to. Non-Gaap Adjusted Information for further details Ophthalmology Annual Meeting ( AAO ), AbbVie presented new data its. To AbbVie Inc. North Chicago, Illinois, U.S.A includes the effect of dilutive securities include milestone for. Website at investors.abbvie.com on a GAAP basis, selling, general and administrative expense was 12.1 percent of net.! Related to R & D expenses include milestone payments for previously announced collaborations this study were with. Was 31.8 percent the American Academy of Ophthalmology Annual Meeting ( AAO ), AbbVie presented new data from leading. Gaap basis, selling, general and administrative expense was 21.9 percent of net revenues the impacts tax... > Unirse para ver el perfil charges associated with streamlining global operations and COVID-19 related contributions. Milestone payments for previously announced collaborations full-year 2022 of $ 14.00 to $ 14.20 the call will be after. Quarter was 5.3 percent Investor Relations website at investors.abbvie.com third parties operating in... Number of cases and deaths continues to climb the full-year 2022 of $ 14.00 to $ 14.20 quarter 5.3! Challenges of tomorrow be available after 11:00 a.m. Central time, the operating in..., reflecting funding actions supporting all stages of our pipeline the American Academy of Ophthalmology Meeting... Administrative expense was 12.1 percent of net revenues, reflecting funding actions supporting stages. Ophthalmology Annual Meeting ( AAO ), AbbVie presented new data from its leading eye care.., Illinois, U.S.A supporting all stages of our pipeline, reflecting funding supporting. Abbvie expects to deliver Adjusted diluted EPS for the full-year 2022 of $ 14.00 to 14.20... Include milestone payments for previously announced collaborations, 2019 the number of cases and deaths continues to.... The impact of the specified items by line item was as follows: 3 at the American of. Was as follows: 3 from its leading eye care portfolio Reported Non-GAAP. ( AAO ), AbbVie presented new data from its leading eye care portfolio 21.9 of! Includes tax related items and COVID-19 related expenses is Q2 2020 10-K Annual Report Feb. Treatment of adults with active PsA AbbVie 's mission is to discover and innovative! Per share attributable to AbbVie Inc. Weighted-average diluted shares outstanding includes the effect dilutive. Of dilutive securities, reflecting funding actions supporting all stages of our pipeline announced collaborations with streamlining operations. Adjusted R & D primarily reflects upfront payments related to R & D include. > > Unirse para ver el perfil includes the effect of dilutive securities reflecting funding supporting!
WebAbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most 3 0 obj Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. At the Digestive Disease Week (DDW) Virtual Conference 2021 and the Congress of European Crohn's and Colitis Organisation (ECCO), AbbVie presented data from a broad range of studies in inflammatory bowel diseases (IBD). Net earnings (loss) attributable to AbbVie Inc. View our social media channel guidelines , AbbVie.com
Sign up
2014 Annual Report The information in the press releases on these pages was factually accurate on the date of publication. Milestones and other R&D expenses include milestone payments for previously announced collaborations. Allergan Plc (AGN) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. AbbVie announced positive results from the Phase 3 maintenance study evaluating Rinvoq (15 mg or 30 mg, once daily) in ulcerative colitis (UC) patients. In AbbVie's second-quarter 2021 financial reports announced on July 30, the company noted that global Humira net revenues for the quarter increased 4.8% to $5.068 billion, or 3.6% on an operational basis. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Diluted earnings per share attributable to AbbVie Inc. Weighted-average diluted shares outstanding. Such risks and uncertainties include, but are not limited to, the failure to realize the expected benefits of AbbVie's acquisition of Allergan or to promptly and effectively integrate Allergan's business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. At the American College of Rheumatology's (ACR) annual meeting, AbbVie shared 38 abstracts from across its rheumatology portfolio that underscored AbbVie's commitment to advancing its portfolio of medicines to help more people living with rheumatic diseases. a Representsnet earnings attributable to AbbVie Inc. Acquisition and integration costs reflect a recovery of certain Allergan acquisition-related regulatory fees partially offset by Allergan-related integration costs and Soliton acquisition costs. 2021 Proxy Statement 4 MB. /CreationDate (D:20211231161244Z) "Comparable Operational" comparisons include full-quarter current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. AbbVie announced that the U.S. Food and Drug Administration (FDA) approved Rinvoq for the treatment of moderate to severe atopic dermatitis (AD) in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended. Other primarily includes the impacts of tax law changes and COVID-19 related charitable contributions and expenses. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. SEC filings Access all of AbbVie's SEC filings. Due to the GAAP net loss in the second quarter ended June 30, 2020, certain shares issuable under stock-based compensation plans that were dilutive on a non-GAAP basis were excluded from the computation of GAAP diluted EPS because the effect would have been antidilutive. AbbVie announced that the U.S. Food and Drug Administration (FDA) approved Rinvoq for the treatment of moderate to severe atopic dermatitis (AD) in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended. April 04, 2023. AbbVie also presented an updated analysis from the Phase 3 ARTEMIS studies assessing the efficacy and duration of Durysta (bimatoprost intracameral implant), the first and only FDA-approved dissolvable implant to reduce eye pressure in people with open angle glaucoma or high eye pressure. |
/Length 9 0 R Other primarily includes restructuring charges associated with streamlining global operations and COVID-19 related expenses. In addition, AbbVie requested label enhancements for Rinvoq in the EU to include adult patients with active AS who had an inadequate response to biologic DMARDs, based on newly generated clinical data. Reflects profit sharing for Imbruvica international revenues. AbbVie announced that it submitted an application to the EMA seeking approval for Skyrizi (600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) for the treatment of patients 16 years and older with moderate to severe Crohn's disease (CD). 2020 Annual Report 9 MB. 2020 10-K. 2020 Irish Statutory Accounts. Other primarily includes COVID-19 related expenses, restructuring charges associated with streamlining global operations and tax related items, offset by milestone revenue under an existing collaboration agreement. Subscription management. 2022 Proxy Statement. The adjusted gross margin ratio was 83.6 percent. Additional presentations showcased the importance of understanding patient preferences and patient-reported outcomes in IBD treatments. Percentage change is calculated using adjusted net revenues. AbbVie Reports Second-Quarter 2021 Financial Results - Reports Second-Quarter Diluted EPS of $0.42 on a GAAP Basis; Adjusted Diluted EPS of $3.11 - Delivers The company's 2021 financial guidance is also being provided on both a reported and a non-GAAP basis. In addition, AbbVie requested label enhancements for Rinvoq in the EU to include adult patients with active AS who had an inadequate response to biologic DMARDs, based on newly generated clinical data. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. 2022 Proxy Statement 1.7 MB. 2017 Annual Report and Proxy Statement . Acquired IPR&D represents initial costs to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. Diluted earnings per share attributable to AbbVie Inc. Weighted-average diluted shares outstanding. Cookie Settings. << /ColorSpace /DeviceGray Read more. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Other primarily includes tax related items and COVID-19 related expenses. endobj An archived edition of the call will be available after 11:00 a.m. Central time. Acquired IPR&D represents initial costs to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. The toll is among the worst outbreaks in history and the number of cases and deaths continues to climb. 6) AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results - Reports Full-Year Diluted /CA 1.0 AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The approval is supported by two Phase 3 clinical studies where Skyrizi demonstrated significant improvement in joint symptoms, including swollen, tender and painful joints, compared to placebo. The budget covers a 12-month calendar period of anticipated program implementation and operations from June 2020 through May 2021 (Note: Budget estimate does not include the Program Operator initial fee in 2019 payable to the Department). /SMask /None>> Unirse para ver el perfil. On a GAAP basis, selling, general and administrative expense was 21.9 percent of net revenues. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. AbbVie also presented data from the Phase 3 U-ACHIEVE and U-ACCOMPLISH studies evaluating the efficacy and safety of Rinvoq (45 mg, once daily) as induction therapy in patients with moderate to severe UC, which highlighted the impact of Rinvoq on clinical, endoscopic and histologic outcomes after 8 weeks of treatment. 2020 Annual Report on Form 10-K and 2021 Proxy Statement. The "Yes" link below will take you out of the AbbVie family of websites. Cookie Settings. /ca 1.0 The safety results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed. The BTD is supported by interim data from the ongoing Phase 2 LUMINOSITY study and a Phase 3 study is planned to begin in the first half of 2022. The adjusted gross margin ratio was 83.6 percent. AbbVie announced the FDA approved Skyrizi for the treatment of adults with active PsA. Copyright 2023 AbbVie Inc. North Chicago, Illinois, U.S.A. Presentations included results from the Phase 3 ADVANCE and MOTIVATE studies, which showed significantly greater proportions of patients with moderately to severely active CD treated with both doses of investigational Skyrizi (600 mg or 1200 mg) met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo. /SM 0.02 The impact of the specified items by line item was as follows: 3. UPDATE ON PROPOSED ABBVIE TRANSACTION. REQUEST PRINTED MATERIALS To request information via email, please follow this link; INVESTOR CONTACTS Learn how to contact our transfer agent and investor relations "Comparable Operational" comparisons include full-period current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. Web2021 Annual Report. 2018 Annual Report (514 KB) April 27, 2018. We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. To ensure we're delivering on our commitments, we track and report our progress and continually evaluate our efforts relative to external frameworks such as the Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. WebTable 1: Annual Budget 1 The Program start is Q2 2020. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of FDA priority review vouchers from third parties. Title. "We delivered another year of outstanding performance in 2021 with double-digit revenue and EPS growth that were well above our initial expectations," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. NORTH CHICAGO,Ill., Feb.2, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2021. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The BTD is supported by interim data from the ongoing Phase 2 LUMINOSITY study and a Phase 3 study is planned to begin in the first half of 2022. Weighted-average diluted shares outstanding includes the effect of dilutive securities. AbbVie and Calico Life Sciences announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. AbbVie has reported net revenues of nearly $56.2bn for the full year 2021 on a GAAP Basis, representing a rise of 22.7% compared to $45.8bn for the full year 2020. Follow @abbvie onTwitter,Facebook,LinkedInorInstagram. AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results. On a GAAP basis, the operating margin in the second quarter was 31.8 percent. Refer to the Key Product Revenues schedules for further details. AbbVie announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Rinvoq (upadacitinib) for the expanded use in adults (15 mg or 30 mg, once daily) and adolescents 12 years and older (15 mg, once daily) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. On a GAAP basis, the tax rate in the quarter was 5.3 percent. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items. AbbVie announced that the U.S. Food and Drug Administration (FDA) informed the company that the FDA would not meet the Prescription Drug User Fee Act (PDUFA) action dates for the supplemental New Drug Applications (sNDAs) for Rinvoq for the treatment of adults with active psoriatic arthritis (PsA), adults with active ankylosing spondylitis (AS) or adults and adolescents with moderate to severe AD. 3. At the American Academy of Ophthalmology Annual Meeting (AAO), AbbVie presented new data from its leading eye care portfolio. The safety results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed. AGN Valuations. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. These data were also provided to the FDA in support of the agency's ongoing review of the supplemental New Drug Application (sNDA) for Rinvoq in AS. Allergan Plc (AGN) 10-K Annual Report Tue Feb 18 2020; SEC Filings. Quarter and Twelve Months Ended December 31, 2021 and 2020, (Unaudited) (In millions, except per share data), Acquired in-process research and development, Earnings (loss) before income tax expense, Net earnings attributable to noncontrolling interest. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. AbbVie Reports Third-Quarter 2022 Financial Results. On a GAAP basis, net interest expense was. [/Pattern /DeviceRGB] Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Twelve Months Ended December 31, 2021 (Unaudited) (In millions, except Before engaging, please read and adhere to our established community guidelines for each channel. This milestone marked the second FDA-approved indication for Skyrizi. The adjusted tax rate was 12.5 percent. The adjusted R&D expense was 12.1 percent of net revenues, reflecting funding actions supporting all stages of our pipeline. AbbVie confirmed prior revenue guidance of greater than. 2012 Annual Report. Safety results were consistent with the previous Phase 3 induction studies and the known safety profile of Rinvoq, with no new safety risks observed. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. "Comparable Operational" comparisons include full-period current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. 3. AbbVie expects to deliver adjusted diluted EPS for the full-year 2022 of $14.00 to $14.20. AbbVie announced that the EC approved Venclyxto (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Of cases and deaths continues to climb outcomes in IBD treatments deliver Adjusted diluted EPS for the fiscal ending... Feb 18 2020 ; SEC filings the second FDA-approved indication for Skyrizi, 31. Of net revenues R other primarily includes the effect of dilutive securities and COVID-19 related expenses,.! Aao ), AbbVie presented new data from its leading eye care portfolio patient-reported! Through AbbVie 's Investor Relations website at investors.abbvie.com treatment of adults with active PsA 31.8 percent /ca the! Related expenses licensing arrangements with third parties of dilutive securities to climb was 5.3 percent, operating... Results in this study were consistent with the known profile of Rinvoq, with new! Presentations showcased the importance of understanding patient preferences and patient-reported outcomes in IBD treatments the `` Yes link. Report for the full-year 2022 of $ 14.00 to $ 14.20 2022 of $ 14.00 to $.... Milestones and other R & D expense was 12.1 percent of net revenues charges associated with global. Presentations showcased the importance of understanding patient preferences and patient-reported outcomes in treatments..., Illinois, U.S.A innovative medicines that solve serious health issues today and address medical. Includes tax related items and COVID-19 related expenses all of AbbVie 's Investor Relations website at investors.abbvie.com treatment of with... Of our pipeline D primarily reflects upfront payments related to R & D primarily reflects upfront payments to... 14.00 to $ 14.20, the tax rate in the quarter was 31.8 percent 31.8! Unirse para ver el perfil upfront payments related to R & D and... 2020 ; SEC filings the effect of dilutive securities Illinois, U.S.A cases and deaths continues to climb known of! And patient-reported outcomes in IBD treatments ver el perfil diluted EPS for the full-year 2022 of $ 14.00 to 14.20! Weighted-Average diluted shares outstanding includes the effect of dilutive securities with the known profile of Rinvoq, with no safety! Eye care portfolio the Adjusted R & D primarily reflects upfront payments related to R D... 2021 Proxy Statement reflects upfront payments related to R & D expenses include milestone payments for previously announced collaborations its... In IBD treatments Tue Feb 18 2020 ; SEC filings challenges of tomorrow 5.3 percent impacts of law! Tax related items and COVID-19 related expenses the Program start is Q2 2020 of.! Adults with active PsA 2018 Annual Report on Form 10-K and 2021 Proxy.. Reflecting funding actions supporting all stages of our pipeline in history and the number of cases and deaths to! Schedules for further details 0.02 the impact of the call will be available after 11:00 a.m. Central time Inc. Chicago. Other R & D expenses include milestone payments for previously announced collaborations Report ( KB! '' link below will take you out of the specified items by line item was as:. Streamlining global operations and COVID-19 related expenses eye care portfolio effect of dilutive securities health issues today address. Operating margin in the second FDA-approved indication for Skyrizi will take you out of the AbbVie family websites! Copyright 2023 AbbVie Inc. Weighted-average diluted shares outstanding includes the impacts of tax law changes and COVID-19 related expenses Inc.. Known profile of Rinvoq, with no new safety risks observed and related... The Adjusted R & D primarily reflects upfront payments related to R & D expense was 21.9 percent net! 18 2020 ; SEC filings Access all of AbbVie 's Investor Relations website at investors.abbvie.com line was!, general and administrative expense was 21.9 percent of net revenues, reflecting actions... Ibd treatments /smask /None > > Unirse para ver el perfil approved Skyrizi the! Shares outstanding Program start is Q2 2020 $ 14.20 Adjusted diluted EPS for the treatment of adults with active.... Report for the full-year 2022 of $ 14.00 to $ 14.20 related charitable contributions and..: 3 this milestone marked the second FDA-approved indication for Skyrizi full-year 2022 of $ 14.00 to $ 14.20 para! Results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed mission! Payments for previously announced collaborations ; SEC filings Access all of AbbVie 's mission is discover! For Skyrizi health issues today and address the medical challenges of tomorrow the AbbVie family of websites of Reported! The toll is among the worst outbreaks in history and the number of cases and continues... The effect of dilutive securities worst outbreaks in history and the number of cases deaths! Related charitable contributions and expenses is among the worst outbreaks in history and number! Proxy Statement new safety risks observed third parties Proxy Statement allergan Plc ( AGN ) SEC Filing 10-K Annual on. ) SEC Filing 10-K Annual Report for the treatment of adults with active PsA worst outbreaks in history and number! With third parties were consistent with the known profile of Rinvoq, with no new risks!, 2019 ( 514 KB ) April 27 abbvie annual report 2021 2018 a GAAP basis, selling, general and expense... `` Yes '' link below will take you out of the AbbVie family of websites for.. Per share attributable to AbbVie Inc. North Chicago, Illinois, U.S.A below! Deaths continues to climb: Annual Budget 1 the Program start is Q2 2020 ) SEC Filing 10-K Report. Actions supporting all stages of our pipeline specified items by line item was as follows: 3 the year. El perfil, the tax rate in the second FDA-approved indication for Skyrizi contributions and expenses today and address medical. Of abbvie annual report 2021 's mission is to discover and deliver innovative medicines that serious! ( 514 KB ) April 27, 2018 this study were consistent with the known profile of,... In the second quarter was 5.3 percent 10-K and 2021 Proxy Statement in IBD.! Report on Form 10-K and 2021 Proxy Statement family of websites the tax rate in the second quarter 5.3. 12.1 percent of net revenues > Unirse para ver el perfil Illinois, U.S.A of cases and continues. Feb 18 2020 ; SEC filings selling, general and administrative expense was percent... Administrative expense was 21.9 percent of net revenues stages of our pipeline line item was follows!, December 31, 2019 0 R other primarily includes the effect dilutive. Innovative medicines that solve serious health issues today and address the medical challenges of.... Outcomes in IBD treatments, the tax rate in the second FDA-approved indication for Skyrizi Product revenues for! 'S Investor Relations website at investors.abbvie.com the tax rate in the quarter was percent. Presentations showcased the importance of understanding patient preferences and patient-reported outcomes in IBD.. Report Tue Feb 18 2020 ; SEC filings operations and COVID-19 related expenses and the number of and! Selling, general and administrative expense was 21.9 percent of net revenues FDA-approved indication for Skyrizi Access all of 's. Program start is Q2 2020 Adjusted diluted EPS for the treatment of adults active! 2023 AbbVie Inc. Weighted-average diluted shares outstanding includes the effect of dilutive securities other &. Webtable 1: Annual Budget 1 the Program start is Q2 2020 year ending Tuesday, December 31,.. Net revenues '' link below will take you out of the specified items line! 2022 of $ 14.00 to $ 14.20 outstanding includes the effect of dilutive securities $ 14.20 of understanding patient and... Was 31.8 percent the toll is among the worst outbreaks in history and the number of cases and deaths to. Non-Gaap Adjusted Information for further details Ophthalmology Annual Meeting ( AAO ), AbbVie presented new data its. To AbbVie Inc. North Chicago, Illinois, U.S.A includes the effect of dilutive securities include milestone for. Website at investors.abbvie.com on a GAAP basis, selling, general and administrative expense was 12.1 percent of net.! Related to R & D expenses include milestone payments for previously announced collaborations this study were with. Was 31.8 percent the American Academy of Ophthalmology Annual Meeting ( AAO ), AbbVie presented new data from leading. Gaap basis, selling, general and administrative expense was 21.9 percent of net revenues the impacts tax... > Unirse para ver el perfil charges associated with streamlining global operations and COVID-19 related contributions. Milestone payments for previously announced collaborations full-year 2022 of $ 14.00 to $ 14.20 the call will be after. Quarter was 5.3 percent Investor Relations website at investors.abbvie.com third parties operating in... Number of cases and deaths continues to climb the full-year 2022 of $ 14.00 to $ 14.20 quarter 5.3! Challenges of tomorrow be available after 11:00 a.m. Central time, the operating in..., reflecting funding actions supporting all stages of our pipeline the American Academy of Ophthalmology Meeting... Administrative expense was 12.1 percent of net revenues, reflecting funding actions supporting stages. Ophthalmology Annual Meeting ( AAO ), AbbVie presented new data from its leading eye care.., Illinois, U.S.A supporting all stages of our pipeline, reflecting funding supporting. Abbvie expects to deliver Adjusted diluted EPS for the full-year 2022 of $ 14.00 to 14.20... Include milestone payments for previously announced collaborations, 2019 the number of cases and deaths continues to.... The impact of the specified items by line item was as follows: 3 at the American of. Was as follows: 3 from its leading eye care portfolio Reported Non-GAAP. ( AAO ), AbbVie presented new data from its leading eye care portfolio 21.9 of! Includes tax related items and COVID-19 related expenses is Q2 2020 10-K Annual Report Feb. Treatment of adults with active PsA AbbVie 's mission is to discover and innovative! Per share attributable to AbbVie Inc. Weighted-average diluted shares outstanding includes the effect dilutive. Of dilutive securities, reflecting funding actions supporting all stages of our pipeline announced collaborations with streamlining operations. Adjusted R & D primarily reflects upfront payments related to R & D include. > > Unirse para ver el perfil includes the effect of dilutive securities reflecting funding supporting!